bupropion has been researched along with Disease Models, Animal in 36 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study assessed the effects of co-administration of bupropion with SSRIs: sertraline, paroxetine, citalopram, fluvoxamine, SNRIs: venlafaxine and milnacipran and NRI: desipramine, using an animal model of depression, the forced swimming test in mice." | 7.74 | Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? ( Bourin, M; Hascoet, M; Prica, C, 2008) |
| "In concurrence with clinical findings proposing alleviation of withdrawal states as a possible mechanism of bupropion and nortriptyline's smoking cessation action, both drugs were found to ameliorate somatic signs of nicotine withdrawal in rodents." | 7.74 | Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. ( Shoaib, M; Wing, VC, 2007) |
| "Drug effects on formalin-induced mechanical allodynia were evaluated for comparison." | 5.43 | Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats. ( Leitl, MD; Negus, SS, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) refers to hepatic pathologies, including simple fatty liver (SFL), nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, that may progress to hepatocellular carcinoma." | 5.43 | Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet. ( Cho, HJ; Cho, SJ; Chong, S; Chung, SJ; Kang, IM; Kim, DD; Kim, SB; Lee, JI; Yoon, IS, 2016) |
| "The response frequency to mechanical allodynia in mice was measured with von Frey hairs." | 5.36 | Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. ( Jesse, CR; Nogueira, CW; Wilhelm, EA, 2010) |
| " Here, we explore combination therapy with bupropion (BUP), a putative stimulator of melanocortin pathways, and an opioid antagonist, naltrexone (NAL), to antagonize an inhibitory feedback loop that limits sustained weight reduction." | 5.14 | Rational design of a combination medication for the treatment of obesity. ( Anderson, JW; Atkinson, RL; Cowley, MA; Dunayevich, E; Fujioka, K; Gadde, KM; Greenway, FL; Gupta, AK; Guttadauria, M; O'Neil, P; Schumacher, D; Smith, D; Tollefson, GD; Weber, E; Whitehouse, MJ, 2009) |
| " Lorcaserin (Belviq(®)), phentermine/topiramate combination (Qsymia(®)), and bupropion/naltrexone combination have been demonstrated to be effective for the treatment of obesity, as an adjunct to a reduced-calorie diet and physical activity, although their absolute safety has yet to be established with more widespread use or longer use." | 3.79 | Therapies for obesity and medication-associated weight gain. ( Howland, RH, 2013) |
| "This study assessed the effects of co-administration of bupropion with SSRIs: sertraline, paroxetine, citalopram, fluvoxamine, SNRIs: venlafaxine and milnacipran and NRI: desipramine, using an animal model of depression, the forced swimming test in mice." | 3.74 | Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? ( Bourin, M; Hascoet, M; Prica, C, 2008) |
| "In concurrence with clinical findings proposing alleviation of withdrawal states as a possible mechanism of bupropion and nortriptyline's smoking cessation action, both drugs were found to ameliorate somatic signs of nicotine withdrawal in rodents." | 3.74 | Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. ( Shoaib, M; Wing, VC, 2007) |
| "Bupropion reduced the amplitude and gating of the N40 evoked potential in mice, similar to the P50 and N100 endophenotypes associated with sensory encoding deficits in schizophrenia." | 3.73 | Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. ( Gur, RE; Kanes, SJ; Lerman, C; Liang, Y; Majumdar, S; Maxwell, CR; Siegel, SJ; Trief, DF, 2005) |
| "The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested after intraperitoneal administration in rat models of acute, persistent and neuropathic pain." | 3.73 | Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. ( Blackburn-Munro, G; Nielsen, AN; Pedersen, LH, 2005) |
| "New treatments to combat opiate addiction are sorely needed." | 1.56 | Dextromethorphan and bupropion reduces high level remifentanil self-administration in rats. ( Blair, G; Davis, JM; Ko, A; Levin, ED; Modarres, J; Pace, C; Rezvani, AH; Rose, JE; Wells, C, 2020) |
| "Bupropion was used as a probe substrate for hepatic CYP2B function using rat liver microsomes." | 1.51 | The effect of chronic kidney disease on CYP2B expression and activity in male Wistar rats. ( Kucey, AS; RaoPeters, AAE; Tieu, A; Tonial, NC; Urquhart, BL; Velenosi, TJ, 2019) |
| "Drug effects on formalin-induced mechanical allodynia were evaluated for comparison." | 1.43 | Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats. ( Leitl, MD; Negus, SS, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) refers to hepatic pathologies, including simple fatty liver (SFL), nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, that may progress to hepatocellular carcinoma." | 1.43 | Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet. ( Cho, HJ; Cho, SJ; Chong, S; Chung, SJ; Kang, IM; Kim, DD; Kim, SB; Lee, JI; Yoon, IS, 2016) |
| "Depression is the leading psychiatric disorder with a high risk of morbidity and mortality." | 1.40 | Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice. ( Krakowska, A; Mlyniec, K; Nowak, G; Opoka, W; Ostachowicz, B; Reczynski, W, 2014) |
| "The response frequency to mechanical allodynia in mice was measured with von Frey hairs." | 1.36 | Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. ( Jesse, CR; Nogueira, CW; Wilhelm, EA, 2010) |
| "Bupropion pre-treatment failed to exert a "nicotine-like" action and also failed to attenuate the orderly dose-related discrimination function of nicotine (0." | 1.32 | Investigating the actions of bupropion on dependence-related effects of nicotine in rats. ( Shafait, S; Shoaib, M; Sidhpura, N, 2003) |
| "Nicotine-treated rabbits had 78/440 (17." | 1.32 | Bupropion (Zyban, Wellbutrin) inhibits nicotine-induced viral reactivation in herpes simplex virus type 1 latent rabbits. ( Azcuy, AM; Barker, SA; Hill, JM; Myles, ME; Nguyen, NT; Reisch, ER; Thompson, HW, 2004) |
| "Bupropion is an atypical antidepressant that also has usefulness as a smoking-cessation aid." | 1.32 | Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. ( Blough, BE; Carroll, FI; Damaj, MI; Eaton, JB; Lukas, RJ; Martin, BR; Mirza, S; Navarro, HA, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.78) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (36.11) | 29.6817 |
| 2010's | 18 (50.00) | 24.3611 |
| 2020's | 4 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Blair, G | 1 |
| Wells, C | 1 |
| Ko, A | 1 |
| Modarres, J | 1 |
| Pace, C | 1 |
| Davis, JM | 1 |
| Rezvani, AH | 1 |
| Rose, JE | 1 |
| Levin, ED | 1 |
| Smith, LC | 1 |
| George, O | 1 |
| Horman, T | 1 |
| Fernandes, MF | 1 |
| Zhou, Y | 1 |
| Fuller, B | 1 |
| Tigert, M | 1 |
| Leri, F | 1 |
| Kucey, AS | 1 |
| Velenosi, TJ | 1 |
| Tonial, NC | 1 |
| Tieu, A | 1 |
| RaoPeters, AAE | 1 |
| Urquhart, BL | 1 |
| Söderpalm, B | 1 |
| Danielsson, K | 1 |
| de Bejczy, A | 1 |
| Adermark, L | 1 |
| Ericson, M | 1 |
| Crespi, F | 1 |
| Howland, RH | 1 |
| Carvalho, MM | 1 |
| Campos, FL | 1 |
| Coimbra, B | 1 |
| Pêgo, JM | 1 |
| Rodrigues, C | 1 |
| Lima, R | 1 |
| Rodrigues, AJ | 1 |
| Sousa, N | 1 |
| Salgado, AJ | 1 |
| Maciel, IS | 1 |
| Silva, RB | 1 |
| Morrone, FB | 1 |
| Calixto, JB | 1 |
| Campos, MM | 1 |
| Bijlsma, EY | 1 |
| Chan, JS | 1 |
| Olivier, B | 1 |
| Veening, JG | 1 |
| Millan, MJ | 1 |
| Waldinger, MD | 1 |
| Oosting, RS | 1 |
| Nunes, EJ | 1 |
| Randall, PA | 1 |
| Hart, EE | 1 |
| Freeland, C | 1 |
| Yohn, SE | 1 |
| Baqi, Y | 1 |
| Müller, CE | 1 |
| López-Cruz, L | 1 |
| Correa, M | 1 |
| Salamone, JD | 1 |
| Mlyniec, K | 1 |
| Ostachowicz, B | 1 |
| Krakowska, A | 1 |
| Reczynski, W | 1 |
| Opoka, W | 1 |
| Nowak, G | 1 |
| El Mansari, M | 1 |
| Manta, S | 1 |
| Oosterhof, C | 1 |
| El Iskandrani, KS | 1 |
| Chenu, F | 1 |
| Shim, S | 1 |
| Blier, P | 1 |
| Leitl, MD | 1 |
| Negus, SS | 1 |
| Cho, SJ | 1 |
| Kim, SB | 1 |
| Cho, HJ | 1 |
| Chong, S | 1 |
| Chung, SJ | 1 |
| Kang, IM | 1 |
| Lee, JI | 1 |
| Yoon, IS | 1 |
| Kim, DD | 1 |
| Stasiuk, W | 1 |
| Szopa, A | 1 |
| Serefko, A | 1 |
| Wyska, E | 1 |
| Świąder, K | 1 |
| Dudka, J | 1 |
| Wlaź, P | 1 |
| Poleszak, E | 1 |
| Prica, C | 1 |
| Hascoet, M | 2 |
| Bourin, M | 2 |
| Greenway, FL | 1 |
| Whitehouse, MJ | 1 |
| Guttadauria, M | 1 |
| Anderson, JW | 1 |
| Atkinson, RL | 1 |
| Fujioka, K | 1 |
| Gadde, KM | 1 |
| Gupta, AK | 1 |
| O'Neil, P | 1 |
| Schumacher, D | 1 |
| Smith, D | 1 |
| Dunayevich, E | 1 |
| Tollefson, GD | 1 |
| Weber, E | 1 |
| Cowley, MA | 1 |
| Lipina, T | 1 |
| Roder, J | 1 |
| Jesse, CR | 1 |
| Wilhelm, EA | 1 |
| Nogueira, CW | 1 |
| Krivisky, K | 1 |
| Ashkenazy, T | 1 |
| Kronfeld-Schor, N | 1 |
| Einat, H | 1 |
| Takechi, K | 1 |
| Suemaru, K | 1 |
| Kawasaki, H | 1 |
| Araki, H | 1 |
| Shoaib, M | 2 |
| Sidhpura, N | 1 |
| Shafait, S | 1 |
| Ripoll, N | 1 |
| David, DJ | 1 |
| Dailly, E | 1 |
| Cryan, JF | 1 |
| Gasparini, F | 1 |
| van Heeke, G | 1 |
| Markou, A | 1 |
| Myles, ME | 1 |
| Azcuy, AM | 1 |
| Nguyen, NT | 1 |
| Reisch, ER | 1 |
| Barker, SA | 1 |
| Thompson, HW | 1 |
| Hill, JM | 1 |
| Damaj, MI | 1 |
| Carroll, FI | 1 |
| Eaton, JB | 1 |
| Navarro, HA | 1 |
| Blough, BE | 1 |
| Mirza, S | 1 |
| Lukas, RJ | 1 |
| Martin, BR | 1 |
| Siegel, SJ | 1 |
| Maxwell, CR | 1 |
| Majumdar, S | 1 |
| Trief, DF | 1 |
| Lerman, C | 1 |
| Gur, RE | 1 |
| Kanes, SJ | 1 |
| Liang, Y | 1 |
| Berrettini, WH | 1 |
| Lerman, CE | 1 |
| Pedersen, LH | 1 |
| Nielsen, AN | 1 |
| Blackburn-Munro, G | 1 |
| Wilkinson, JL | 1 |
| Palmatier, MI | 1 |
| Bevins, RA | 1 |
| Wing, VC | 1 |
| Sukoff Rizzo, SJ | 1 |
| Schechter, LE | 1 |
| Rosenzweig-Lipson, S | 1 |
| Katz, RJ | 1 |
| Sibel, M | 1 |
4 reviews available for bupropion and Disease Models, Animal
| Article | Year |
|---|---|
Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.
Topics: Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Electronic Nicotine Delivery Syst | 2020 |
Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release?
Topics: Animals; Antidepressive Agents; Aza Compounds; Brain; Bridged Bicyclo Compounds, Heterocyclic; Bupro | 2014 |
Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion.
Topics: Animals; Bupropion; Disease Models, Animal; Extinction, Psychological; Humans; Nicotine; Reinforceme | 2003 |
Pharmacotherapy and pharmacogenetics of nicotine dependence.
Topics: Administration, Cutaneous; Administration, Intranasal; Animals; Animals, Genetically Modified; Bupro | 2005 |
1 trial available for bupropion and Disease Models, Animal
| Article | Year |
|---|---|
Rational design of a combination medication for the treatment of obesity.
Topics: Adult; Animal Feed; Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Drug Therapy, | 2009 |
31 other studies available for bupropion and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Dextromethorphan and bupropion reduces high level remifentanil self-administration in rats.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Bupropion; Dextromethorphan; Disease Models, Animal; | 2020 |
An exploration of the aversive properties of 2-deoxy-D-glucose in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Analysis of Variance; Animals; Beha | 2018 |
The effect of chronic kidney disease on CYP2B expression and activity in male Wistar rats.
Topics: Adenine; Animals; Aryl Hydrocarbon Hydroxylases; Bupropion; Cytochrome P-450 CYP2B1; Disease Models, | 2019 |
Combined administration of varenicline and bupropion produces additive effects on accumbal dopamine and abolishes the alcohol deprivation effect in rats.
Topics: Alcohol-Related Disorders; Animals; Bupropion; Disease Models, Animal; Dopamine; Drug Therapy, Combi | 2020 |
In vivo oxymetric analysis of mild hypercapnia upon cerebral oxygen, temperature and blood flow: markers of mood as proposed by concomitant bupropion challenge and electrochemical analysis?
Topics: Animals; Biomarkers; Brain; Bupropion; Depressive Disorder; Disease Models, Animal; Dopamine; Electr | 2013 |
Therapies for obesity and medication-associated weight gain.
Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined | 2013 |
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion | 2013 |
Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Brain-Derive | 2013 |
Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Sec | 2013 |
Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice.
Topics: Animals; Antidepressive Agents; Bupropion; Citalopram; Copper; Depression; Disease Models, Animal; I | 2014 |
Restoration of serotonin neuronal firing following long-term administration of bupropion but not paroxetine in olfactory bulbectomized rats.
Topics: Action Potentials; Animals; Antidepressive Agents, Second-Generation; Bupropion; CA3 Region, Hippoca | 2014 |
Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats.
Topics: Analgesics; Analgesics, Opioid; Animals; Bupropion; Depression; Disease Models, Animal; Dose-Respons | 2016 |
Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet.
Topics: Animals; Bupropion; Choline; Choline Deficiency; Cytochrome P-450 CYP2B1; Diet, High-Fat; Disease Mo | 2016 |
Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Brain; Bupropion; Chromatography, High Pressur | 2017 |
Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression?
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents, Second-Generatio | 2008 |
A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.
Topics: Amphetamine; Animals; Bupropion; Clozapine; Conditioning, Psychological; Disease Models, Animal; Dop | 2010 |
Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion.
Topics: Amitriptyline; Analgesics; Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depression; | 2010 |
Antidepressants reverse short-photoperiod-induced, forced swim test depression-like behavior in the diurnal fat sand rat: further support for the utilization of diurnal rodents for modeling affective disorders.
Topics: Animals; Antidepressive Agents; Bupropion; Choice Behavior; Circadian Rhythm; Disease Models, Animal | 2011 |
Regulatory role of the dopamine and norepinephrine transporters in pentylenetetrazol-kindled mice: association with effect of antidepressants.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Bupropion; | 2011 |
Investigating the actions of bupropion on dependence-related effects of nicotine in rats.
Topics: Animals; Avoidance Learning; Bupropion; Conditioning, Operant; Discrimination Learning; Disease Mode | 2003 |
Antidepressant-like effects in various mice strains in the tail suspension test.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, An | 2003 |
Bupropion (Zyban, Wellbutrin) inhibits nicotine-induced viral reactivation in herpes simplex virus type 1 latent rabbits.
Topics: Animals; Bupropion; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Interactions; Eye; Fema | 2004 |
Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.
Topics: Animals; Behavior, Animal; Bupropion; Disease Models, Animal; Dopamine Plasma Membrane Transport Pro | 2004 |
Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials.
Topics: Animals; Antipsychotic Agents; Biogenic Monoamines; Bupropion; Disease Models, Animal; Dopamine Upta | 2005 |
Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain.
Topics: Amines; Analgesics; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Bupropio | 2005 |
Preexposure to nicotine alters the subsequent locomotor stimulant effects of bupropion in rats.
Topics: Animals; Behavior, Animal; Bupropion; Central Nervous System Stimulants; Disease Models, Animal; Dop | 2006 |
Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal.
Topics: Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Dose-Response Relationship, Drug; | 2007 |
A novel approach for predicting antidepressant-induced sexual dysfunction in rats.
Topics: Animals; Antidepressive Agents; Bupropion; Desipramine; Disease Models, Animal; Dopamine Agonists; F | 2008 |
Animal model of depression: tests of three structurally and pharmacologically novel antidepressant compounds.
Topics: Animals; Antidepressive Agents; Bupropion; Corticosterone; Depressive Disorder; Disease Models, Anim | 1982 |